Fig. 6.

Baseline serum concentration of MIF and clinical outcomes from another group of patients (n=34). (A) Percentages of patients who had different clinical responses in the low- (n = 26) and high- (n = 8) MIF-level groups. ORR, objective response rate; DCR, disease control rate. Serum MIF levels in R (n = 20) and NR (n = 14) groups (B) before the initiation of the treatment and (C) after two cycles of the treatment. The changes in the serum MIF level in exceptional cases in the (D) R group (n = 7) and (E) NR group (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001.